# Ongericimab Injection Reducing Recurrence of Ischemic Stroke

Study · id `cardio:ct-nct07242599` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07242599](<https://clinicaltrials.gov/study/NCT07242599>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07242599

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4810 participants.

## Technical summary

Registry record NCT07242599. Randomized; single masking; primary purpose treatment. Start 2026-04-22 (anticipated); primary completion 2029-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4810 participants (planned count; ClinicalTrials.gov record NCT07242599, source copy `cardio:ctgov-nct07242599-2026-04-16`, retrieved 2026-10-26)
- Planned start: 2026-04-22 (anticipated) (ClinicalTrials.gov record NCT07242599, source copy `cardio:ctgov-nct07242599-2026-04-16`, retrieved 2026-10-26)
- Primary completion: 2029-04-01 (anticipated) (ClinicalTrials.gov record NCT07242599, source copy `cardio:ctgov-nct07242599-2026-04-16`, retrieved 2026-10-26)
- Completion: 2029-04-01 (anticipated) (ClinicalTrials.gov record NCT07242599, source copy `cardio:ctgov-nct07242599-2026-04-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07242599, source copy `cardio:ctgov-nct07242599-2026-04-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07242599-2026-04-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ongericimab Injection Reducing Recurrence of Ischemic Stroke
- Acronym: ORIS
- Condition: Ischemic Cerebral Infarction
- Intervention (Combination product): High target group
- Intervention (Combination product): Low target group
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 1efc35a1887b8a4033521b43fc74fc536bfc4252540a83d9542c6421c2201904
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
